These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35666956)

  • 1. Matrix Metalloproteinase-2-Responsive Surface-Changeable Liposomes Decorated by Multifunctional Peptides to Overcome the Drug Resistance of Triple-Negative Breast Cancer through Enhanced Targeting and Penetrability.
    Liu C; Zhao Z; Gao R; Zhang X; Sun Y; Wu J; Liu J; Chen C
    ACS Biomater Sci Eng; 2022 Jul; 8(7):2979-2994. PubMed ID: 35666956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
    Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
    Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-functionalized therapeutic nanoplatform for treatment orthotopic triple negative breast cancer and bone metastasis.
    Li D; Ma S; Xu D; Meng X; Lei N; Liu C; Zhao Y; Qi Y; Cheng Z; Wang F
    Nanomedicine; 2023 Jun; 50():102669. PubMed ID: 36933756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer.
    Tezcan O; Elshafei AS; Benderski K; Rama E; Wagner M; Moeckel D; Pola R; Pechar M; Etrych T; von Stillfried S; Kiessling F; Weiskirchen R; Meurer S; Lammers T
    J Control Release; 2023 Feb; 354():784-793. PubMed ID: 36599395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.
    Agnello L; Tortorella S; d'Argenio A; Carbone C; Camorani S; Locatelli E; Auletta L; Sorrentino D; Fedele M; Zannetti A; Franchini MC; Cerchia L
    J Exp Clin Cancer Res; 2021 Jul; 40(1):239. PubMed ID: 34294133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
    Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
    ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
    Chen DR; Lu DY; Lin HY; Yeh WL
    Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
    Hossein-Nejad-Ariani H; Althagafi E; Kaur K
    Sci Rep; 2019 Feb; 9(1):2723. PubMed ID: 30804365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
    Ryu JS; Kratz F; Raucher D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells.
    Pullan J; Dailey K; Bhallamudi S; Feng L; Alhalhooly L; Froberg J; Osborn J; Sarkar K; Molden T; Sathish V; Choi Y; Brooks A; Mallik S
    ACS Appl Bio Mater; 2022 May; 5(5):2163-2175. PubMed ID: 35417133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.